ACM
SUPN icon

Advent Capital Management’s Supernus Pharmaceuticals SUPN Stock Holding History

Advent Capital Management’s Portfolio SUPN Stock Details SUPN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q4 		– Sell
-15,000
Closed -$755K – 326
2018
Q3 		$755K Buy
+15,000
New +$741K 0.02% 189
2013
Q4 		– Sell
-15,490
Closed -$114K – 613
2013
Q3 		$114K Sell
15,490
-7,010
-31% -$47.1K ﹤0.01% 573
2013
Q2 		$145K Buy
+22,500
New +$133K ﹤0.01% 529

Other funds holding SUPN

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
CIP
Champlain Investment Partners Burlington, Vermont $7.88B AUM 6.82% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return
Fiera Capital (Canada)
Fiera Capital (Canada) Montreal, Quebec, Canada $29.2B AUM 20.16% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
RHJA
Rice Hall James & Associates San Diego, California $1.8B AUM 36.16% 1-Year Est. Return

Advent Capital Management's SUPN Position: Q4 2018 in Review

Advent Capital Management sold out of Supernus Pharmaceuticals (SUPN) in Q4 2018, closing a stake of 15,000 shares — an estimated $755K sold.

Advent Capital Management first reported a position in SUPN in Q2 2013 and held it in 3 quarters. The position peaked at $755K in Q3 2018. 274 funds tracked by Wall St. Rank hold SUPN as of Q4 2018.

  • Advent Capital Management reported no remaining Supernus Pharmaceuticals position as of Q4 2018 after selling out during the quarter.
  • Advent Capital Management sold 15,000 Supernus Pharmaceuticals shares in Q4 2018, an estimated $755K.
  • Advent Capital Management first reported a position in Supernus Pharmaceuticals in Q2 2013 and held it in 3 quarters.
  • Advent Capital Management's Supernus Pharmaceuticals position peaked at $755K in Q3 2018.
  • 274 funds tracked by Wall St. Rank held Supernus Pharmaceuticals as of Q4 2018.

Based on Advent Capital Management's 13F filing for Q4 2018, filed 14 Feb 2019.